Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
-
Recent Posts
- The Cost of Price: Why and How to Get Beyond Intellectual Property Internalism
- WHA 65 adopted the resolution for way forward on CEWG report on R&D
- Corporations Win Big in Battle Against Investment Regulation
- US and EU Derailing Ten-year Process to Create Health Research & Development Convention
- MSF: Update on debates at World Health Assembly on a possible R&D convention, 23 May 2012
Categories
Tag Archives: Antiretroviral drug
Brazilians demand greater access to crucial HIV drug
Source: www.msfaccess.org Civil society files patent opposition to increase access to HIV/AIDS medicines Rio de Janeiro, 10 November 2011 – Brazilian civil society will oppose a patent application today for the key HIV drug lopinavir/ritonavir (LPV/r), in an effort to … Continue reading
ITPC Groups Launch Global Campaign Against Abbott Labs’ Monopoly on Critical AIDS Medicine
Public Health Groups Launch Global Campaign Against Abbott Labs’ Monopoly on Critical AIDS Medicine Groups Seek Generic Competition for Abbott’s Patented Lifesaving Treatments WASHINGTON, D.C. – Today, public health groups in a dozen countries launch a campaign to challenge Abbott … Continue reading
Posted in Drug Pricing, Generic drug, HIV/Aids, patent
Tagged Abbott, Antiretroviral drug, Kaletra, Lopinavir, Ritonavir, World Trade Organization
1 Comment
Controversial Trans-Pacific Free Trade Talks End
Progress Illinois Aaron Krager, Friday September 16th Trade talks for a Trans-Pacific Free Trade Agreement ended yesterday at the Hilton Hotel in the world’s fourth most economically powerful city in the world. It seems only fitting Chicago, a city with … Continue reading
Shooting Itself In the Foot: The Broken Promises of the U.S. Trade Agenda
Source: Huffington Post As United States trade representatives thrash out an international trade deal in Chicago, truly ominous developments are unfolding behind the scenes. Leaked drafts of the U.S. position show that the government is pushing provisions to tighten intellectual … Continue reading
Drug company Novartis tries to weaken Indian patent law that protects people
Geneva/New Delhi 5 September 2011 – Novartis will go before the Indian Supreme Court tomorrow in the latest attempt by the Swiss multinational pharmaceutical company to undermine a key public health safeguard in Indian patent law specifically designed to prevent … Continue reading
A Trade Barrier to Defeating AIDS
By TINA ROSENBERG July 26, 2011 Earlier this month, the patent pool received its first donation of rights from a pharmaceutical manufacturer, Gilead Sciences. It is an important step — but the terms Gilead negotiated are also confirmation of a … Continue reading
The Implications of the Medicines Patent Pool and Gilead Licenses on Access to Treatment
Briefing Paper by ITPC & I-MAK On 12 July, 2011 the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. (Gilead) announced they had entered into a licensing agreement to improve access to anti-retrovirals (ARVs) and Hepatitis B (HBV) treatment in … Continue reading
Posted in Generic drug, HIV/Aids, Medicine Patent Pool
Tagged Antiretroviral drug, Gilead Sciences, Patent pool, Unitaid
Leave a comment
Corporate Self-Interest And Strategic Choices: Gilead Licenses To Medicines Patent Pool
Published on 21 July 2011 @ 8:50 pm Intellectual Property Watch By Prof. Brook K. Baker, Health GAP Summary: Despite some important advances to the scope of its previous purely voluntary licenses on key antiretroviral medicines, Gilead’s licenses with the UNITAID-sponsored … Continue reading
Posted in Drug Pricing, Generic drug, HIV/Aids, Medicine Patent Pool
Tagged Antiretroviral drug, Gilead Sciences, Patent pool, Unitaid
Leave a comment
Open letter from Latin-American civil society groups on the ‘MPP’ agreement with Gilead
The first license signed between the “Medicines Patent Pool” (MPP) and a pharmaceutical company frustrated the expectations of civil society groups in several countries. Launched as an innovative mechanism to promote access to patented medicines in developing and least developed … Continue reading
Posted in Generic drug, HIV/Aids, Medicine Patent Pool
Tagged Antiretroviral drug, Latin America
Leave a comment
Open Letter from Thai Civil Society: One Step forward, Two Steps back: the Agreement between the Medicine Patent Pool and Gilead Sciences, Inc
On behalf of the Thai Network of People Living with HIV & AIDS, pharmaceutical academics and civil society organisations working on access to medicines for all in Thailand, we wish to raise our grave concerns regarding the agreement between the … Continue reading
Posted in Generic drug, HIV/Aids, Medicine Patent Pool
Tagged Antiretroviral drug, Generic drug, Gilead Sciences, Patent pool, Thailand
Leave a comment
